Home > The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder.

Batki, Steven and Ciccarone, Daniel and Hadland, Scott E and Hurley, Brian and Kabernagel, Kimberly and Levin, Frances and McKay, James R and Mooney, Larissa and Puri, Siddarth and Saxon, Andrew and Sevarino, Kevin and Simon, Kevin M and Wiegand, Timothy and Boyle, Maureen and Devoto, Amanda and Framnes-DeBoer, Sarah and Safarian, Taleen and Cates-Wessel, Kathryn and Dirst, Michelle and Lindsay, Dawn and Lincoln, Piper and Helmick, Jillian and Luongo, Peter (2024) The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. Journal of Addiction Medicine, 18, (1S Suppl 1), pp. 1-56. DOI: 10.1097/ADM.0000000000001299.

External website: https://journals.lww.com/journaladdictionmedicine/...


The American Society of Addiction Medicine/American Academy of Addiction Psychiatry (ASAM/AAAP) Clinical Practice Guideline on the Management of Stimulant Use Disorder provides guidance on evidence-based strategies for the treatment of stimulant use disorders (StUDs), stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use. The Clinical Guideline Committee (CGC) comprised experts from ASAM and AAAP representing a range of clinical settings and patient populations. The guideline was developed following modified GRADE methodology. The process included a systematic literature review as well as several targeted supplemental searches. The CGC utilized Evidence to Decision tables to review available evidence and rate the strength of each recommendation. The clinical practice guideline was revised based on external stakeholder review. Key takeaways included: Contingency management represents the current standard of care for treatment of StUDs; Pharmacotherapies may be utilized off-label to treat StUDs; Acute stimulant intoxication can result in life-threatening complications that should be addressed in an appropriate level of care; Secondary and tertiary prevention strategies should be used to reduce harms related to risky stimulant use.

[You can also view the electronic provider pocket guide of the guidelines, and the patient pocket guide]

Repository Staff Only: item control page